Positron Emission Tomography News and Research

RSS

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.

11 Dec 2012

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy.

11 Dec 2012

Combination of diagnostic tests can predict conversion from MCI to Alzheimer's

A combination of diagnostic tests, including imaging and cerebrospinal fluid biomarkers can improve prediction of conversion from mild cognitive impairment (MCI) to Alzheimer's disease, according to a new study published online in the journal Radiology.

11 Dec 2012

Studies explore F-18-FLT PET utility in providing prognostic information for patients with gliomas

In the management of gliomas-or tumors that originate in the brain-precise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival.

4 Dec 2012

Evidence of neurobiologic differences between bipolar subtypes

Taiwanese researchers have found differences in fronto-limbic metabolism and executive function between patients with bipolar disorder I and II.

30 Nov 2012

Florbetapir PET scans can detect brain amyloid deposits associated with Alzheimer’s

A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.

28 Nov 2012

Chemotherapy can induce brain changes that may affect concentration and memory

Chemotherapy can induce changes in the brain that may affect concentration and memory, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

27 Nov 2012

New combinations of medical imaging technologies hold promise for personalized medicine

New combinations of medical imaging technologies hold promise for improved early disease screening, cancer staging, therapeutic assessment, and other aspects of personalized medicine, according to Ge Wang, director of Virginia Tech's Center for Biomedical Imaging, in a recent paper that appeared in the refereed journal PLoS One.

27 Nov 2012

Personality influences placebo response

Researchers have found that resilient, altruistic, and straightforward individuals are significantly more likely to respond to a sham painkilling or placebo injection than those who are angry and hostile.

21 Nov 2012

Personality traits linked with individual's susceptibility to placebo effect from pain medicines

Personality traits might do more than help you win a popularity contest. According to new University of Michigan-led neuroscience research, co-authored by University of Maryland (UM) School of Dentistry Dean Christian S. Stohler, DMD, DrMedDent, such traits also might make you more likely to get pain relief from a placebo - a fake medicine.

17 Nov 2012

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose parkinsonian syndromes.

15 Nov 2012

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C 11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent prostate cancer. Mayo Clinic is the first, and currently only, institution in North America approved to produce this imaging agent.

9 Nov 2012

EUROECHO 2012 reveals how imaging improves early diagnosis of atherosclerosis

"Atherosclerosis is the leading cause of cardiovascular disease and the leading killer in Europe," said Professor Patrizio Lancellotti, President-Elect of the EACVI and Chairman of the EUROECHO Scientific Programme Committee. "Many of these deaths could be averted by diagnosis at a preclinical stage or early after the onset of symptoms."

8 Nov 2012

Studies shake up Alzheimer’s hypotheses

Two studies in people at genetic risk for Alzheimer’s disease reveal very early changes in brain structure and function that may actually precede amyloid beta deposition.

6 Nov 2012

Anti-TNF-α therapy reduces CVD risk in patients with rheumatoid arthritis

Patients with rheumatoid arthritis exhibit a sub-clinical vasculitis that may underlie their increased risk for cardiovascular disease, shows research.

5 Nov 2012

PET scans allow scientists to study link between caffeine and neurodegenerative disorders

Molecular imaging with positron emission tomography (PET) has enabled scientists for the first time to visualize binding sites of caffeine in the living human brain to explore possible positive and negative effects of caffeine consumption.

2 Nov 2012

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center, a leading oncology research institution, has enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, esophageal, prostate, ovarian, pancreatic and head & neck cancer.

26 Oct 2012

Positron Emission Tomography News and Research

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Combination of diagnostic tests can predict conversion from MCI to Alzheimer's

Studies explore F-18-FLT PET utility in providing prognostic information for patients with gliomas

Evidence of neurobiologic differences between bipolar subtypes

Florbetapir PET scans can detect brain amyloid deposits associated with Alzheimer’s

Chemotherapy can induce brain changes that may affect concentration and memory

New combinations of medical imaging technologies hold promise for personalized medicine

Personality influences placebo response

Personality traits linked with individual's susceptibility to placebo effect from pain medicines

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

EUROECHO 2012 reveals how imaging improves early diagnosis of atherosclerosis

Studies shake up Alzheimer’s hypotheses

Anti-TNF-α therapy reduces CVD risk in patients with rheumatoid arthritis

PET scans allow scientists to study link between caffeine and neurodegenerative disorders

UWCCC enrolls first patient in Phase 1-2 PET imaging trial of LIGHT for solid tumors

Omega-3 fatty acid can enhance cognition in highly functional young individuals

F-18-FLT-PET predicts early response to chemoradiotherapy in head and neck cancer

FDG–PET/CT improves staging and modifies radiotherapy management

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News